Skip to content

A pilot study of the tolerability and effect on smoking urges of flavoured and unflavoured nicotine inhalers that contain either pure nicotine or a nicotine salt, compared to placebo.

A semi-randomised placebo-controlled cross-over pilot study in heavy smokers, of flavoured and unflavoured nicotine base and nicotine lactate pressurised metered-dose formulations, comparing their tolerability and effect on smoking urges .

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12611001006932
Acronym
INHALE-pilot
Enrollment
12
Registered
2011-09-20
Start date
2011-10-10
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The aim of this small study, is to test the tolerability, efficacy, and side-effects of a series of placebo and nicotine inhaler formulations. We aim to test whether a menthol inhaler can act as a convincing placebo intervention. We aim to test whether pure nicotine (nicotine free base) is more or less tolerable to inhaler than nicotine lactate; and whether the addition of menthol, or vanillin improves the tolerability of these formulations.

Interventions

All subjects will inhale one puff from a series of placebo and nicotine formulations during one visit to the clinic, which will last approximately 1 to 3 hours. Initially subjects will take just one puff of each formulation and rate its effects. They will wait until they feel another urge to smoke before they try one puff of the next formulation. All subjects will begin with the lowest dose of the placebo formulations (0.5% menthol), have one puff, then progress to the 0.75% menthol dose (whe

All subjects will inhale one puff from a series of placebo and nicotine formulations during one visit to the clinic, which will last approximately 1 to 3 hours. Initially subjects will take just one puff of each formulation and rate its effects. They will wait until they feel another urge to smoke before they try one puff of the next formulation. All subjects will begin with the lowest dose of the placebo formulations (0.5% menthol), have one puff, then progress to the 0.75% menthol dose (when they feel an urge to smoke), then they will go on to take one puff of the 1% dose (when they feel an urge to smoke). When subjects once again feel an urge to smoke, they will take up to ten puffs of the highest dose of the placebo formulation that they found tolerable and effective, and rate its effects. Then subjects will be randomised to take one puff of a range of 50mcg nicotine doses in random cross-over order. All these puffs will be taken on the same day, subjects will be asked to delay taking a puff of the next formulation until they once again feel an urge to smoke. The formulations that subjects will take in random order are: nicotine base, nicotine base plus menthol, nicotine base plus vanillin, nicotine lactate, nicotine lactate plus menthol, nicotine lactate plus vanillin. Subjects may then choose whether or not to take one puff of the 100mcg per puff dose of one or more of the formulations of which they sampled the 50mcg dose version (presented in the same random order as the 50mcg doses were). Subjects will only take a puff of the 100mcg dose of those formulations which they thought the 50mcg dose was tolerable. Subjects will take one puff of each of the 100mcg dose formulations, and after taking a puff of one formulation, they will wait until they feel an urge to smoke before they take a puff of the next formulation. Subjects can then choose to inhale one or more of the 200mcg doses of those formulations which they thought were tolerable at the lower doses. Just as they did with the lower dose formulations, before they take one puff of each of the 200mcg formulations, they will wait until they feel an urge to smoke before they take a puff of the next formulation, and they will only inhaler the higher dose of those formulations for which they felt the lower dose was tolerable. Subjects may then sample up to ten puffs of one or more of the formulations, which they thought was the most tolerable and efficacious. Subjects will be encouraged to choose the highest dose of the formulations that they thought were tolerable and efficacious (in terms of reducing the urge to smoke). The time over which subjects inhale the ten puffs will be limited to a maximum of ten minutes, and subjects can have a shorter duration if they wish. Subjects will wait until they feel an urge to smoke before they try the next formulation.

Sponsors

Health Research Council of New Zealand
Lead SponsorGovernment body

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

Smoke more than 9 cigarettes per day. Have a brief-Fagerstrom Test of Nicotine Dependence score of 3 or more.

Exclusion criteria

uncontrolled hypertension, uncontrolled diabetes, history of unstable angina or heart attack or stroke in the past 3 months, uncontrolled phaeochromocytoma, uncontrolled hyperthyroidism, psychiatric disorder severe enough to require ongoing care of a psychiatrist, pregnancy, breastfeeding, inadequate contraception, current use of any nicotine replacement therapy, taking medications that are metabolised by cytochrome CYP1A2 (imipramine, clozapine, opioid analgesics (e.g. propoxyphene), propranolol, verapamil, theophylline, insulin, pentazocline, tacrine, ropinirole, olanzapine, clomiprasmine, fluvoxamine)

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026